VIATRIS INC. Restructuring and Related Cost, Expected Number of Positions Eliminated
VIATRIS INC. (VTRS) reported Restructuring and Related Cost, Expected Number of Positions Eliminated of 45.00 thousand agreement for the 3-month period ending 2020-12-31, per its 10-K filed 2021-03-01.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated · last filed 2021-03-01
- VIATRIS INC. restructuring and related cost, expected number of positions eliminated for the quarter ending 2020-12-31 was 45.00K agreement.
| Period end | Restructuring and Related Cost, Expected Number of Positions Eliminated 3 month |
|---|---|
| 2020-12-31 | 45.00K agreement 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |